Shareholder Alert: Ademi LLP investigates whether Intercept Pharmaceuticals, Inc. has obtained a Fair Price in its transaction with Alfasigma

Author's Avatar
Sep 26, 2023

PR Newswire

MILWAUKEE, Sept. 26, 2023 /PRNewswire/ -- Ademi LLP is investigating Intercept (Nasdaq: ICPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Alfasigma.


Click here to learn how to join the action or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Intercept stockholders are expected to receive only $19 per share in cash. The transaction agreement unreasonably limits competing transactions for Intercept by imposing a significant penalty if Intercept accepts a competing bid. Intercept insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Intercept's board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Intercept common stock and wish to obtain additional information, please contact Guri Ademi either at [email protected] or toll-free: 866-264-3995, or

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.


Ademi LLP
Guri Ademi
Toll Free: (866) 264-3995
Fax: (414) 482-8001

favicon.png?sn=CG20487&sd=2023-09-26 View original content to download multimedia: